Show simple item record

Biomarcadores en Espondiloartropatías.

dc.contributores-ES
dc.creatorRomero-Sánchez, Consuelo; Servicio de Reumatología - Hospital Militar Central/Universidad de la Sabana|Instituto UIBO-Universidad El Bosque
dc.creatorLondoño, John; Servicio de Reumatología - Hospital Militar Central/Universidad de la Sabana
dc.creatorDe Avila, Juliette; Instituto UIBO-Universidad El Bosque
dc.creatorValle-Oñate, Rafael; Servicio de Reumatología - Hospital Militar Central/Universidad de la Sabana
dc.date2010-09-08
dc.date.accessioned2019-11-11T18:28:08Z
dc.date.available2019-11-11T18:28:08Z
dc.identifierhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/view/232
dc.identifier.urihttps://revistaschilenas.uchile.cl/handle/2250/111473
dc.descriptionIntroduction: Study of biomarkers (defined as molecules that reflect a biologic or specific pathological process) in rheumatic disease including spondyloarthropathies (SpA), has emerged as an important and necessary area among basic and clinic investigation, can be considered to reflect a biologic or specific pathological process, it’s consequence or the response to an intervention, there are others that provide information about the disease pathogenesis. In SpA has not been possible to find other biomarkers, and to assess the activity, it is necessary to resort to clinical test, as Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Bath Ankylosing Spondylitis Functional Index (BASFI), since erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) have demonstrated to be poor biomarkers, indicating us that the search of those in SpA must continue. Objective: To describe the state the art of research of biomarkers of activity aimed at measuring and understanding of the pathogenesis in spondyloarthropathies. Results: The ESR and CRP have shown poor performance measurement of activity. New candidates have been reported as promising as metalloproteinase 3, neopeptido C2C collagen, C propeptide of type II collagen, agrecan 846, colony stimulating factor Macrophage, serum amyloid A protein, IL-6, soluble CD14 among others, allowing direct the search for these markers related to immune response. Conclusions: The rapid progression of the treatments with anti-TNF-alpha demand to have available methods to demonstrate in a sure way the asses of the activity due to it’s high costs in our environment. Thus it is necessary to establish objective measurements that help to rationalize resources. Previous Studies have allowed to orient the search of this markers related to the immune response.es-ES
dc.languagees
dc.publisherRevista Médica de Chilees-ES
dc.sourceRevista Médica de Chile; Vol. 138, núm. 9 (2010): SEPTIEMBRE 2010es-ES
dc.source0034-9887
dc.subjectes-ES
dc.titleBiomarcadores en Espondiloartropatías.es-ES
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.typees-ES


This item appears in the following Collection(s)

Show simple item record